Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Our Top 10 High Growth Dividend Stocks - July 2025
08:00am, Saturday, 19'th Jul 2025
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:50am, Friday, 18'th Jul 2025
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Explore the HIV market with our comprehensive report, analyzing disease overview, epidemiology, and current treatments. Discover unmet needs, R&D strategies, and market trends from 2023-2033 in the 7
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
10:00am, Thursday, 17'th Jul 2025
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
10:00am, Thursday, 17'th Jul 2025
NEW YORK , July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised
Why Merck Is A Better Dividend Stock Than Gilead Sciences
03:08pm, Wednesday, 16'th Jul 2025
I reiterate my Hold rating on Merck & Co., Inc. and downgrade Gilead Sciences, Inc. to Sell, as MRK outperforms on dividend growth and valuation metrics. Compared to GILD, MRK features a longer divide
GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm
03:12am, Wednesday, 16'th Jul 2025
LOS ANGELES , July 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gilead Sciences, In
Here's Why Gilead Sciences (GILD) Fell More Than Broader Market
07:01pm, Tuesday, 15'th Jul 2025
Gilead Sciences (GILD) closed at $109.06 in the latest trading session, marking a -2.7% move from the prior day.
GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm
07:08pm, Monday, 14'th Jul 2025
LOS ANGELES--(BUSINESS WIRE)---- $GILD--GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm.
WHO recommends Gilead's twice-yearly injection for HIV prevention
02:48pm, Monday, 14'th Jul 2025
The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.
Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025
09:30am, Monday, 14'th Jul 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 PURPOSE trial data at IAS 2025 showing tha
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
10:00am, Saturday, 12'th Jul 2025
NEW YORK , July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advise
Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock
10:50am, Thursday, 10'th Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
07:01pm, Wednesday, 09'th Jul 2025
In the most recent trading session, Gilead Sciences (GILD) closed at $113.24, indicating a +1.96% shift from the previous trading day.
AHF: Gilead's Greed Costs Latin America HIV Protection
04:37pm, Wednesday, 09'th Jul 2025
MEXICO CITY--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV p
